An Analysis of the PANORAMA 1 Trial

Angela Dispenzieri, MD
Published Online: July 11, 2014
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.

Clinical Pearls:
  • This was a positive study in terms of progression-free survival. The progression-free survival was about 4 months better in the panobinostat arm.
  • There were significantly more grade 3 toxicities, such as diarrhea, thrombocytopenia and fatigue, in the panobinostat arm.
  • There is no signal in terms of better overall survival.

Related Articles
Irene Ghobrial, MD, director, Michele & Stephen Kirsch Laboratory, senior physician, Dana-Farber Cancer Center Institute, discusses the novel anti-CXCR4 ulocuplumab for the treatment of multiple myeloma.
One of the leading non-clinical attributes that affect how oncologists decide which therapeutic agent to prescribe over another is patient affordability.
Denise A. Yardley, MD, from Sarah Cannon Research Institute, discusses toxicities associated with treatment with PI3K inhibitors for breast cancer.
Anti-CD38 monoclonal antibodies continue to demonstrate promise and generate excitement that a new treatment paradigm could be on the horizon for patients with multiple myeloma.
JTT Articles
Soft Tissue Sarcomas: Emerging and Novel Concepts
Management of Hepatocellular Cancer
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
External Resources

Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Targeted Communications
Connect With Us:

About Us
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.